Awarding Institution: Marquis Who’s Who in America in 2024
Who is Eligible to Compete: This recognition is limited to individuals who possess professional integrity, demonstrate outstanding achievement in their respective field and have made innumerable contributions to society as a whole.
Selection Criteria: Every year Marquis Who’s Who America selects an elite list of the top three percent of the professionals in the world who have excelled in their fields. Individuals who have demonstrated longevity, leadership, and prominence in their field are eligible for this honor.
The award justification description:
Aram Ghalali, faculty at Harvard Medical School and assistant professor at Karolinska Institutet in Sweden, has been recognized by Marquis Who’s Who Top Scientists for dedication, achievements, and leadership in surgical instruction.
Dr. Ghalali’s research has great importance because it seeks therapies that address the complex biochemical influences on one of the world’s most burdensome diseases, cancer. His research is pharmacogenetic in nature because it closely examines the epigenetic regulation of various factors in cellular health. Pharmacogenetics is considered a breakthrough for cancer treatment because it considers phenotype-genotype correlations to provide personalized diagnoses and treatment plans to optimize the effectiveness of therapy. Therefore, Dr. Ghalali is actively engaged with a cutting-edge subject in cancer therapy to address the most globally harmful forms of cancer.
In his research Dr. Ghalali has used innovative techniques to improve the quality of cancer care in the United States, even for forms of cancer that are notoriously difficult to treat. This is most readily apparent in Dr. Ghalali’s research on prostate cancer, and childhood brain cancers. The American Cancer Society has reported that prostate cancer is the most common form of non-melanoma cancer for American men, with nearly a quarter of a million new cases and deaths in excess of 34,000 expected by the end of 2021. At its current incidence, 1 out of every 8 American men is diagnosed with prostate cancer in his lifetime. However, research on the subject has stalled due to the genetic complexity of prostate cancer, which is shaped by a wide range of somatic mutations, including extensive copy number alterations, chromatin structure and single-nucleotide polymorphisms as well as germline predispositions and the complex epigenetic effects of small noncoding RNA molecules. Dr. Ghalali is one of the only researchers to effectively harness the power of oncogenic signaling pathways and translate them into practical clinical strategies for the reduction of prostate cancer risk. Additionally, Dr. Ghalali has made important discoveries in the field of childhood brain cancers and also other types of cancers, among them lung and liver cancers. Furthermore, he is currently leading a multidisciplinary interinstitutional team, in Europe, focusing on environmental medicine. For these mentioned reasons, his research is indispensable for public health in the United States.
Finally, Dr. Ghalali is a rising star who will not be stopped on the road to having a significant impact on the lives of cancer patients. Based on this multifactorial assessment, it is clear that Dr. Ghalali’s education, experience, expertise, documented record of success, influence in his field, and his future plan have altogether well positioned him to receive the professional title: Top Scientists in the year 2024, by Marquis Who’s Who.
For more information, click here.
